Keywords: hemodialysis, hepatitis B virus, hepatitis C virus, direct acting antivirals, infection control 〈Abstract〉 Hepatitis B virus(HBV)and hepatitis C virus(HCV)infection rates have been reported to be higher in patients receiving hemodialysis(HD)treatment than in the general population. Eighty-two outpatients used the dialysis facilities at Ehime Prefectural Central Hospital from 2016-2018. Of these, 31(37.8%)patients tested positive for anti-hepatitis B surface antigen and/or anti-hepatitis B core antigen(HBc)antibodies, including 6 patients who tested positive for anti-HBc antibodies alone. The 31 patients all tested negative for HBV-DNA. Eight(9.7%) patients tested positive for anti-HCV antibodies, 6 of whom tested positive for HCV-RNA. Among the HCV-RNA-positive patients, 4 were positive for genotype 1, and 2 were positive for genotype 2. Five of these patients received direct-acting antivirals. All 5 patients exhibited sustained virological responses at 24 weeks after treatment(SVR24)Creating a portable flowchart can help raise awareness of infection countermeasures.